18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Treatment Efficacy and Clinical Outcome for Patients With Pancreatic Carcinoma A Meta-analysis

被引:17
|
作者
Wang, Li [1 ]
Dong, Ping [2 ]
Shen, Guohua [2 ]
Hou, Shengzhong [1 ]
Zhang, Yi [1 ]
Liu, Xubao [1 ]
Tian, Bole [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Pancreat Surg, 37 Guoxue Rd, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Nucl Med, Chengdu, Sichuan, Peoples R China
关键词
pancreatic carcinoma; FDG-PET; SUVmax; prognosis; treatment assessment; STANDARDIZED UPTAKE VALUE; TOTAL LESION GLYCOLYSIS; METABOLIC TUMOR VOLUME; PROGNOSTIC VALUE; FDG-PET; F-18-FDG PET/CT; DUCTAL ADENOCARCINOMA; RESPONSE EVALUATION; DISTANT METASTASIS; CANCER;
D O I
10.1097/MPA.0000000000001375
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives F-18-Fluorodeoxyglucose positron emission tomography (FDG-PET) has been an important modality for detecting malignancies. Recently, an increasing number of studies reported the utility of FDG-PET parameters in predicting clinical outcomes and treatment assessment in variety of cancers. We aimed at clarifying both the prognostic role and assessment value of FDG-PET in pancreatic carcinoma. Methods We systematically searched electronic databases of PubMed, Embase, Cochrane Library, and Web of Science to identify relevant studies to conduct this meta-analysis. Comparative analyses of the pooled hazard ratio (HR) for overall survival were performed to assess the utility of FDG-PET parameters in prognosis evaluation and treatment assessment by random-effect model. Results Twenty-three studies with 1762 patients met the inclusion criteria of this meta-analysis. The pooled results revealed that greater maximum standardized uptake value of the primary tumor was significantly correlated with poorer overall survival (HR, 1.31; 95% confidence interval, 1.15-1.50; P < 0.001). Besides, greater reduction of maximum standardized uptake value after treatments indicated significant better overall survival (HR, 0.68; 95% confidence interval, 0.47-0.98; P = 0.037). Conclusions F-18-Fluorodeoxyglucose positron emission tomography parameters might be helpful not only for predicting survival outcome but also for selecting potentially efficacious treatments in patients with pancreatic carcinoma.
引用
收藏
页码:996 / 1002
页数:7
相关论文
共 50 条
  • [41] The Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma
    Yoon, Hong In
    Kim, Kyung Hwan
    Lee, Jeongshim
    Roh, Yun Ho
    Yun, Mijin
    Cho, Byoung Chul
    Lee, Chang Geol
    Keum, Ki Chang
    CANCER RESEARCH AND TREATMENT, 2016, 48 (03): : 928 - 941
  • [42] Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma
    Lim, Chae Hong
    Moon, Seung Hwan
    Cho, Young Seok
    Choi, Joon Young
    Lee, Kyung-Han
    Hyun, Seung Hyup
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (08) : 1705 - 1712
  • [43] The value of 18F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis
    Hassanzadeh-Rad, Arman
    Yousefifard, Mahmoud
    Katal, Sanaz
    Asady, Hadi
    Fard-Esfahani, Armaghan
    Jafari, Ali Moghadas
    Hosseini, Mostafa
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (05) : 929 - 935
  • [44] Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy
    Barnes, Chad A.
    Aldakkak, Mohammed
    Clarke, Callisia N.
    Christians, Kathleen K.
    Bucklan, Daniel
    Holt, Michael
    Tolat, Parag
    Ritch, Paul S.
    George, Ben
    Hall, William A.
    Erickson, Beth A.
    Evans, Douglas B.
    Tsai, Susan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [45] 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy
    Hodolic, Marina
    Topakian, Raffi
    Pichler, Robert
    RADIOLOGY AND ONCOLOGY, 2016, 50 (03) : 247 - 253
  • [46] Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of small cell carcinoma of the prostate
    Sahiner, I.
    Akkas, B. E.
    Vural, G. Ucmak
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2013, 32 (03): : 193 - 195
  • [47] Using 18F-Fluorodeoxyglucose Positron Emission Tomography to Monitor Clinical Outcomes in Patients Treated With Neoadjuvant Chemo-Radiotherapy for Locally Advanced Pancreatic Cancer
    Choi, Minsig
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Lawhorn-Crews, Jawana M.
    Zalupski, Mark M.
    Shields, Anthony F.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (03): : 257 - 261
  • [48] The 18F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer
    Mihailovic, Jasna
    Ubavic, Milan
    VOJNOSANITETSKI PREGLED, 2017, 74 (06) : 571 - 580
  • [49] 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma
    Cosimo Sperti
    Claudio Pasquali
    Franca Chierichetti
    Andrea Ferronato
    Giandomenico Decet
    Sergio Pedrazzoli
    Journal of Gastrointestinal Surgery, 2003, 7 : 953 - 960
  • [50] 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma
    Sperti, C
    Pasquali, C
    Chierichetti, F
    Ferronato, A
    Decet, G
    Pedrazzoli, S
    JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (08) : 953 - 959